{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.02","value":"-2.30"},{"groupId":"OG001","spread":"16.04","value":"-5.72"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"EORTC QLQ-C30 is a generic questionnaire consisting of 30 items. The instrument yields functional scales (physical, role, emotional, cognitive, social), symptom scales/items (fatigue, Nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea), global health status, and financial impact score. Most items are scored 1 (\"not at all\") to 4 (\"very much\") except for the items contributing to the global health status/QoL, which are scored 1 (\"very poor\") to 7 (\"excellent\"). The recall period for each question is \"during the past week\". All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. Higher scores on the global health status and functioning scales indicate better health status/function.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 1.25 mg/kg of body weight enfortumab vedotin by IV infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.","id":"OG000","title":"Enfortumab Vedotin 1.25 mg/kg"},{"description":"Participants received either 75 mg/m\\^2 docetaxel by IV infusion over approximately 1 hour or 320 mg/m\\^2 vinflunine by IV infusion over approximately 20 minutes or 175 mg/m\\^2 paclitaxel by IV infusion over approximately 3 hours on day 1 of every 21-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEAN","populationDescription":"FAS population with available data.","reportingStatus":"POSTED","timeFrame":"Baseline and week 12","title":"Change From Baseline to Week 12 in European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire Global Health Status (QL2 Score)","type":"SECONDARY","unitOfMeasure":"score on a scale"}